Selected article for: "initial treatment and ivig resistance CAL development"
Author: Kang, Soo Jung; Kim, Nam Su
Title: Association of Toll-like receptor 2-positive monocytes with coronary artery lesions and treatment nonresponse in Kawasaki disease
  • Document date: 2017_7_31
    • ID: tk1bxztw_47
    Snippet: Our results showed that FTLR2% before the initial treatment is a more sensitive predictor of CAL development than sIL10 in patients with KD. sIL10 before treatment was shown to be elevated in pati ents with acutestage KD, and its cutoff values for the prediction of CAL development and IVIG resistance have been previously proposed 27) . We found that sIL10 before treatment in the CAL (+) group was not significantly higher than that in the CAL () g.....
    Document: Our results showed that FTLR2% before the initial treatment is a more sensitive predictor of CAL development than sIL10 in patients with KD. sIL10 before treatment was shown to be elevated in pati ents with acutestage KD, and its cutoff values for the prediction of CAL development and IVIG resistance have been previously proposed 27) . We found that sIL10 before treatment in the CAL (+) group was not significantly higher than that in the CAL () group. The reason for this finding might be that, in our study, patients be longing to the CAL (+) group were those that had developed CALs at one month after diagnosis. High sIL10 at the acute stage of KD might have had a cumulative beneficial effect on the inflammation of the coronaries past the acute stage of KD, as IL10 is known to have both antiinflammatory and proinflammatory properties 19, 20) .

    Search related documents:
    Co phrase search for related documents
    • acute stage and CAL development: 1, 2
    • acute stage and CAL group: 1
    • acute stage and cutoff value: 1
    • acute stage and initial treatment: 1, 2
    • acute stage and IVIG resistance: 1, 2
    • acute stage and KD acute stage: 1, 2, 3, 4, 5, 6
    • beneficial effect and initial treatment: 1, 2, 3, 4, 5
    • cal develop and IVIG resistance: 1
    • CAL development and cutoff value: 1
    • CAL development and initial treatment: 1, 2, 3, 4
    • CAL development and IVIG resistance: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • CAL development and IVIG resistance CAL development: 1, 2, 3, 4, 5, 6, 7, 8
    • CAL group and initial treatment: 1, 2, 3, 4
    • CAL group and IVIG resistance: 1, 2, 3, 4
    • CAL group and IVIG resistance CAL development: 1, 2, 3
    • CAL treatment and initial treatment: 1, 2, 3, 4, 5
    • CAL treatment and IVIG resistance: 1, 2, 3, 4, 5
    • CAL treatment and IVIG resistance CAL development: 1, 2
    • cutoff value and initial treatment: 1